brotizolam
Trade name: Lendormin
Small moleculeexperimental
Brotizolam is a sedative-hypnotic thienotriazolodiazepine drug which is a benzodiazepine analog. It possesses anxiolytic, anticonvulsant, hypnotic, sedative and skeletal muscle relaxant properties, and is considered to be similar in effect to other short-acting hypnotic benzodiazepines such as triazolam or midazolam. It is used in the short-term treatment of severe insomnia. Brotizolam is a highly potent and short-acting hypnotic, with a typical dose ranging from 0.125 to 0.25 milligrams, which is rapidly eliminated with an average half-life of 4.4 hours. — Wikipedia
Clinical trial activity
7 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
3
Phase 3
3
Phase 4
0
Earliest trial started Mar 1, 2000 (NCT02218671)
Timeline
Indications
Mechanism of action
Chemistry & pharmacology
Loading structure…
SMILES
CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C- Mol. weight
- 414.72 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaBrotizolam ↗
- ChEMBLCHEMBL53569 ↗
- ChEMBLCHEMBL32479 ↗
- ChEMBLCHEMBL221542 ↗
Also known as
- 2-bromo-4-(2-chlorophenyl)-9-methyl-6h-thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepine
- brotizolam
- brotizolam
- brotizolam
- brotizolam
- brotizolam
- brotizolam
- brotizolam
- brotizolam
- brotizolam
- brotizolamum
- brotizolamum
- europharma brand of brotizolam
- lendorm
- lendorm
- lendorm
- lendorm
- lendormin
- lindormin
- mederantil
- promeco brand of brotizolam
- sintonal
- we 941
- we 941
- we 941
- we-941
- we-941
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02776228 | Phase 3 | Dec 1, 2016 | Technion University |
| NCT02374567 | Phase 3 | Jan 1, 2015 | Gottfried Wilhelm Leibniz Universität Hannover |
| NCT01361022 | Phase 1 | Aug 1, 2011 | Boehringer Ingelheim |
| NCT00347295 | Phase 3 | Jun 1, 2006 | Boehringer Ingelheim |
| NCT02218645 | Phase 1 | Aug 1, 2000 | Boehringer Ingelheim |
| NCT02218658 | Phase 1 | Jul 1, 2000 | Boehringer Ingelheim |
| NCT02218671 | Phase 1 | Mar 1, 2000 | Boehringer Ingelheim |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Boehringer Ingelheim | For profit | 5 | 5 | 2 | 2000 |
| Gottfried Wilhelm Leibniz Universität Hannover | Academic/Hospital | 1 | 1 | 1 | 2015 |
| Technion University | Academic/Hospital | 1 | 1 | 1 | 2016 |
3 organizations
Page 1 / 1